Yuanbin Chen

机构：Cancer Treatment Centers of America, Hematology Oncology Consultants · ORCID：0009-0006-4175-8055

发表论文 150 篇 · 总被引 734 次 · h-index 10

代表论文

• 297MO: Patterns of disease progression with durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Results from ADRIATIC (2025 · Journal of Thoracic Oncology · 被引 6)
• 1601O 3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801 (2025 · Annals of Oncology · 被引 5)
• Clinical and molecular characteristics of early progressors (EPs) and long-term progression-free survivors (LTPs) from the phase 3 ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC). (2025 · Journal of Clinical Oncology · 被引 2)
• Abstract CT094: Durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Outcomes by PD-L1 expression in ADRIATIC (2025 · Cancer Research · 被引 2)
• Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1 (2026 · Cancer Discovery)
• A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250) (2025 · ESMO Open)